Report: FDA expected to OK 3rd vaccine dose for the immunocompromised
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
The Food and Drug Administration is preparing to revise its emergency use authorizations for the Pfizer and Moderna COVID-19 vaccines, allowing immunocompromised adults to get a third dose, two people familiar with the matter told NBC News.
The announcement is expected to come on Thursday, the people said. Both the Pfizer and Moderna vaccines involve two shots, but there is evidence that people who are immunocompromised may only develop low levels of antibodies after being vaccinated, if any at all. A recent study at Johns Hopkins University of organ transplant recipients, who take medicine to suppress their immune systems so their new organs aren't rejected, showed that a third vaccine dose increased their antibody levels.
In July, an advisory panel to the Centers for Disease Control and Prevention said extra doses must be approved for immunocompromised adults, who make up about 2.7 percent of the U.S. population.
Article continues belowThe Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
